Pharvaris N.V.
Pharvaris N.V. (PHVS): 1 pipeline candidate · 4 upcoming catalysts · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 0.11 · 0% dilution
Lead: Phase 3
1 candidate
4 upcoming, next in ~44d
0 buys · 35 sells (180d)
A transparent, data-derived signal for Pharvaris N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.2B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| deucrictibant | Phase 3 |
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
108
Total value held
$1.32B
| Holder | Shares | Value |
|---|---|---|
| general atlantic, l.p. | 8,031,252 | $226.9M |
| fmr llc | 6,284,472 | $177.5M |
| viking global investors lp | 3,653,310 | $103.2M |
| eqt fund management s.a r.l. | 3,424,609 | $96.7M |
| deerfield management company, l.p. | 3,126,042 | $88.3M |
| wellington management group llp | 2,118,900 | $59.9M |
| commodore capital lp | 1,918,970 | $54.2M |
| novo holdings a/s | 1,750,000 | $49.4M |
| saturn v capital management lp | 1,201,402 | $33.9M |
| point72 asset management, l.p. | 1,007,016 | $28.4M |
Showing top 10 of 108 institutional holders of Pharvaris N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Pharvaris N.V.'s pipeline?
Pharvaris N.V. (PHVS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pharvaris N.V.'s lead drug candidate?
Pharvaris N.V.'s most advanced tracked candidate is deucrictibant (Phase 3) for Hereditary Angioedema; Hereditary Angioedema (HAE); Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH).
What is Pharvaris N.V.'s next catalyst?
Pharvaris N.V.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of" — expected August 1, 2026.
What is Pharvaris N.V.'s market capitalization?
Pharvaris N.V.'s market capitalization is approximately $2.2B.
Who is the CEO of Pharvaris N.V.?
Mr. Berndt Axel Edvard Modig CPA, M.B.A. is the chief executive officer of Pharvaris N.V. (PHVS).
Get the full picture on Pharvaris N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.